Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti CD44v6 chimeric antigen receptor T cell therapy - AGC Biologics

Drug Profile

Research programme: anti CD44v6 chimeric antigen receptor T cell therapy - AGC Biologics

Alternative Names: CAR-CD44v6 immune gene therapy - MolMed; CAR-T CD44v6; CARCD44v6; Chimeric antigen receptor CD44v6 immune gene therapy - AGC Biologics

Latest Information Update: 28 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Scientific Institute San Raffaele
  • Developer AGC Biologics; Scientific Institute San Raffaele
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • No development reported Haematological malignancies; Solid tumours

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for preclinical development in Haematological-malignancies in Italy (IV)
  • 19 Jan 2022 AGC Biologics terminates a phase I/II trial in Acute myeloid leukemia in Czechia republic and Italy (NCT04097301)
  • 07 Sep 2019 MolMed plans the first-in-human phase I/IIa EURE-CART1 trial for Acute myeloid leukaemia and Multiple myeloma (In infants, In children, In adolescents, In adults, In the elderly, Second-line therapy or greater, Refractory metastatic disease) in Czech Republic (IV, Infusion) , (EudraCT2018-000813-19)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top